☆ 4.6 Review

Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors

Kaysia Ludford et al.

Summary: Pembrolizumab has shown significant clinical benefits in advanced MSI-H/dMMR solid tumors. This phase II trial evaluated the use of pembrolizumab in neoadjuvant treatment for localized unresectable or high-risk resectable MSI-H/dMMR tumors. The study demonstrated high rates of response and safety, suggesting potential implications for organ-sparing strategies.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer

Bin-Yi Xiao et al.

Journal of the National Comprehensive Cancer Network (2023)

Add to Collection

Article Multidisciplinary Sciences

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

Natasja L. de Vries et al.

Summary: DNA mismatch repair-deficient (MMR-d) cancers with inactivation of beta 2-microglobulin (B2M) retained responsiveness to immune checkpoint blockade (ICB) and showed increased infiltration by gamma delta T cells expressing PD-1 and high reactivity to HLA-class-I-negative tumour cells. Dual PD-1 and CTLA-4 blockade increased the frequency of gamma delta T cells in B2M-deficient cancers, suggesting the potential of gamma delta T cells in cancer immunotherapy.

NATURE (2023)

Add to Collection

Article Immunology

Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer

Long Zhou et al.

Summary: This study aimed to explore the clinical effect of neoadjuvant immunotherapy in non-metastatic colorectal cancer. Through the analysis of ten articles and 410 cases, it was found that neoadjuvant immunotherapy could increase the rates of pathological complete response and major pathological response. Subgroup analysis showed that the rate of pathological complete response was higher in the deficient mismatch repair/microsatellite instability-high group (dMMR/MSI-H) compared to the proficient mismatch repair/microsatellite stable group (pMMR/MSS). In conclusion, neoadjuvant immunotherapy could be another treatment option for non-metastatic colorectal cancer.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Oncology

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer

Javier Ros et al.

Summary: Immune checkpoint inhibitors have revolutionized the prognosis for several tumor types, but have shown limited success in treating metastatic colorectal tumors that are microsatellite stable (MSS). However, recent studies have demonstrated promising results with novel combinations of immune checkpoint inhibitors in MSS colorectal cancer. This review examines the underlying biological factors contributing to the lack of response to immunotherapy in MSS colorectal cancer and explores potential strategies to overcome innate resistance mechanisms.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Oncology

Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments

J. Ros et al.

Summary: This study aimed to evaluate the prognostic and predictive role of plasma BRAF allele fraction (AF) in BRAF-V600E-mutant metastatic colorectal cancer (mCRC) patients. The results showed that patients with high BRAF AF had lower progression-free survival (PFS) and overall survival (OS), and they may benefit from triplet therapy. Therefore, plasma BRAF AF can serve as a reliable indicator of tumor burden and aggressiveness, and can guide treatment decisions.

ANNALS OF ONCOLOGY (2023)

Add to Collection

Article Oncology

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

A. Cervantes et al.

ANNALS OF ONCOLOGY (2023)

Add to Collection

Article Oncology

Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164

Dung T. Le et al.

Summary: The study demonstrated that Pembrolizumab had durable clinical benefit and manageable safety in previously treated MSI-H/dMMR colorectal cancer patients. It showed persistent antitumor activity, prolonged overall survival, and tolerable safety profile.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

Joris van de Haar et al.

Summary: Genomic analysis identified KRAS(G12) mutations as potential biomarkers of resistance to trifluridine/tipiracil treatment in metastatic colorectal cancer. Real-world data and phase 3 clinical trial data confirmed the significant association between KRAS(G12) mutations and reduced overall survival. These findings provide important implications for precision medicine in approximately 28% of patients with metastatic colorectal cancer.

NATURE MEDICINE (2023)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

Claus Garbe et al.

Summary: Individuals with cutaneous melanoma who receive neoadjuvant immunotherapy demonstrate significant improvement, which should be included in standard care.

NATURE MEDICINE (2023)

Add to Collection

Article Oncology

BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

Raphael Colle et al.

Summary: This study evaluated the prognostic value of RAS/BRAF(V600E) mutations and Lynch syndrome on immune checkpoint inhibitor-treated metastatic colorectal cancer patients with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR). The results showed that RAS/BRAF(V600E) mutations were not associated with survival, while Lynch syndrome conferred an improved progression-free survival.

ONCOLOGIST (2023)

Add to Collection

Article Medicine, General & Internal

Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab

Bahar Saberzadeh-Ardestani et al.

Summary: This cohort study found clinically significant prolongation of survival in older patients with dMMR mCRC who received first-line pembrolizumab monotherapy in routine clinical practice. Liver metastasis was associated with poorer survival compared to nonliver metastasis, indicating the importance of metastatic site in survival outcome.

JAMA NETWORK OPEN (2023)

Add to Collection

Article Oncology

Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability- high metastatic colorectal cancer treated with immune checkpoint inhibitors

Paolo Manca et al.

Summary: Immune checkpoint inhibitors (ICIs) are the standard treatment for patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). Tumour mutational burden (TMB) is a promising biomarker for predicting treatment outcomes.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers

Javier Ros et al.

Summary: The presence of a BRAF-V600E mutation in metastatic colorectal cancer (mCRC) is associated with poor prognosis. The development of successful BRAF inhibitors in colorectal cancer has been complex, but the BEACON trial made progress by establishing encorafenib-cetuximab as a new standard of care. However, not all patients respond to this treatment, so new strategies are necessary.

EXPERT REVIEW OF ANTICANCER THERAPY (2023)

Add to Collection

Article Oncology

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Heinz-Josef Lenz et al.

Summary: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (P1CC): a single-centre, parallel-group, noncomparative, randomised, phase 2 trial

Huabin Hu et al.

Summary: The study showed that neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer. This treatment was associated with a high pathological complete response rate and an acceptable safety profile, which did not compromise surgery. Longer term follow-up is needed to assess effects on survival-related endpoints.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Biology

Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade

Alecsandra Gorzo et al.

Summary: Colorectal cancer is the third most common cancer in Western countries and remains a leading cause of death despite advances in screening and early detection methods. Recent research has focused on understanding the interaction between the immune system and cancer cells. While immune checkpoint inhibitors have shown effectiveness in various cancers, their benefit in colorectal cancer is limited. However, a subset of patients with a specific genetic profile has been found to have a prolonged response to these inhibitors. This review aims to discuss the current knowledge on immunotherapy in colorectal cancer and explore potential strategies to overcome resistance.

LIFE-BASEL (2022)

Add to Collection

Article Oncology

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy

Julio Garcia-Aguilar et al.

Summary: This study demonstrates that organ preservation is achievable in patients with locally advanced rectal cancer treated with total neoadjuvant therapy, without a decrease in survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy

Chenzhi Zhang et al.

Summary: Mutations in B2M and JAK1/2 do not cause primary resistance to anti-PD-1 therapy in colorectal carcinoma patients. Patients with JAK1/2 mutations even show a better response to anti-PD-1 therapy compared to those without mutations.

JOURNAL OF IMMUNOTHERAPY (2022)

Add to Collection

Article Oncology

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Luis A. Diaz et al.

Summary: The final overall survival analysis of the KEYNOTE-177 study showed that while pembrolizumab continued to demonstrate durable antitumor activity and fewer treatment-related adverse events compared to chemotherapy in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, there was no statistically significant difference in overall survival between the two treatment groups.

LANCET ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer

A. Bullock et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

T. Andre et al.

Summary: This study confirms the long-term benefit of nivolumab plus low-dose ipilimumab for previously treated patients with MSI-H/dMMR mCRC, with a manageable safety profile.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer

Andrea Cercek et al.

Summary: This study found that mismatch repair-deficient, locally advanced rectal cancer is highly sensitive to PD-1 blockade. Additionally, no adverse events of grade 3 or higher have been reported, and no cases of progression or recurrence have been observed. Longer follow-up is needed to assess the duration of response.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article

Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues

Ibrahim Halil Sahin et al.

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting (2022)

Add to Collection

Meeting Abstract Oncology

A phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant MSS metastatic colorectal cancer (mCRC)

M. G. Fakih et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study

M. Chalabi et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis

Yuegang Li et al.

Summary: This study evaluated the efficacy and safety of PD-1/PD-L1 inhibitors in advanced colorectal cancer (CRC). The results showed that anti-PD-1/PD-L1 therapy was associated with improved survival in patients with MSI-H/dMMR advanced CRC. Low expression of PD-L1 may serve as a potential predictive marker for positive response and outcome.

BMC GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial

Julien Taieb et al.

Summary: Immune checkpoint inhibitors have shown limited efficacy in treating metastatic colorectal cancer patients, except those with dMMR/MSI tumors. A comparative phase II trial in France is evaluating the effectiveness and safety of anti-PDL1 Avelumab versus standard second-line treatment in this patient population.

DIGESTIVE AND LIVER DISEASE (2021)

Add to Collection

Meeting Abstract Oncology

Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

Thierry Andre et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer et al.

Summary: The RAPIDO trial aimed to reduce systemic relapses in locally advanced rectal cancer through short-course radiotherapy, chemotherapy, and delayed surgery. Results showed a decreased probability of disease-related treatment failure in the experimental group compared to standard care, with diarrhea being the most common adverse event and neurological toxicity being prominent in the standard care group during adjuvant chemotherapy.

LANCET ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

Jiali Yu et al.

Summary: Liver metastases diminish the efficacy of immunotherapy by siphoning activated CD8(+) T cells from systemic circulation, creating systemic immune desert. Combining liver-directed radiotherapy with immunotherapy can promote systemic antitumor immunity.

NATURE MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts

Michele Bortolomeazzi et al.

Summary: This study conducted a comprehensive analysis of the cellular and molecular determinants of response to anti-PD1 immunotherapy in colorectal cancer patients. The findings revealed that response to immunotherapy was associated with factors such as high clonality of immunogenic mutations and clonally expanded T cells, rather than tumor mutational burden (TMB). Additionally, a population of antigen-presenting macrophages interacting with CD8 T cells consistently segregated with response to anti-PD1 agents.

GASTROENTEROLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

Raphael Colle et al.

Summary: The study found that 10% of patients with MSI/dMMR mCRC treated with ICIs experienced PSPD, with most of them occurring within the first 3 months, representing the majority of primary radiological PDs. There were almost no occurrences of PSPD after 3 months.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Alexander M. Menzies et al.

Summary: A pooled analysis of neoadjuvant immunotherapy trials in melanoma revealed that the degree of pathological response is correlated with patient survival, serving as a potential surrogate marker for long-term outcomes. Patients with pathological complete response (pCR) after immunotherapy showed significantly improved recurrence-free survival (RFS) and overall survival (OS) compared to those without pCR. Pathological response, particularly pCR, could be an early surrogate endpoint for clinical trials and a new benchmark for development and approval in melanoma.

NATURE MEDICINE (2021)

Add to Collection

Article Oncology

Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer

Romain Cohen et al.

Summary: This case series describes five patients with ICI-treated MSI mCRC with disease progression limited to the adrenal glands. The treatment methods included adrenalectomy and stereotactic body radiation therapy, suggesting that the adrenal glands may be the sanctuary sites for ICI-treated MSI mCRC.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Letter Medicine, General & Internal

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors

Benoit Rousseau et al.

Summary: The study demonstrated that improved overall survival in tumors with high mutational burden treated with immune checkpoint inhibitors was mainly associated with mutations in the POLE gene and defective DNA mismatch repair, rather than overall mutational burden.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer

A. Guyot D'Asnieres De Salins et al.

Summary: The study confirmed a high degree of concordance between MSI and MMR IHC tests, emphasizing the importance of reviewing discordant cases and analysis by expert teams.

ESMO OPEN (2021)

Add to Collection

Article Oncology

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Dung T. Le et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer

Zuzana Snahnicanova et al.

CLINICAL AND EXPERIMENTAL MEDICINE (2020)

Add to Collection

Article Immunology

Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer

Neal C. Fiamchander et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Oncology

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer The Canadian Cancer Trials Group CO.26 Study

Eric X. Chen et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Myriam Chalabi et al.

NATURE MEDICINE (2020)

Add to Collection

Article Oncology

Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

G. Argiles et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Review Oncology

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy

J. Haanen et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Oncology

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurelien Marabelle et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

T. Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

Romain Cohen et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Review Oncology

MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors

Magali Svrcek et al.

BULLETIN DU CANCER (2019)

Add to Collection

Meeting Abstract Oncology

Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability high (MSI-H) tumors.

Neil Howard Segal et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

Federico Innocenti et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

A. B. Schrock et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Letter Oncology

Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection

J. Ros et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

CANCER Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response

Rajarsi Mandal et al.

SCIENCE (2019)

Add to Collection

Article Oncology

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer

Thomas Reinert et al.

JAMA ONCOLOGY (2019)

Add to Collection

Review Genetics & Heredity

Best practices for bioinformatic characterization of neoantigens for clinical utility

Megan M. Richters et al.

GENOME MEDICINE (2019)

Add to Collection

Article Pathology

Mutation Burden and I Index for Detection of Microsatellite Instability in Colorectal Cancer by Targeted Next-Generation Sequencing

Jeong E. Kim et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2019)

Add to Collection

Review Oncology

Alternative tumour-specific antigens

Christof C. Smith et al.

NATURE REVIEWS CANCER (2019)

Add to Collection

Article Oncology

High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer

Jonas Janikovits et al.

ONCOIMMUNOLOGY (2018)

Add to Collection

Article Oncology

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Michael J. Overman et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers

Guo-Chen Liu et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Nikolaos Zacharakis et al.

NATURE MEDICINE (2018)

Add to Collection

Article Oncology

Genetic Mechanisms of Immune Evasion in Colorectal Cancer

Catherine S. Grasso et al.

CANCER DISCOVERY (2018)

Add to Collection

Article Oncology

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis et al.

CANCER DISCOVERY (2018)

Add to Collection

Article Oncology

The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers

Guo-Chen Liu et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)

Add to Collection

Meeting Abstract Oncology

Nivolumab in patients with DNA mismatch repairdeficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.

Michael J. Overman et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Review Cell Biology

Immune targets and neoantigens for cancer immunotherapy and precision medicine

Rong-Fu Wang et al.

CELL RESEARCH (2017)

Add to Collection

Article Oncology

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency

R. Cohen et al.

EUROPEAN JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE. Mutation

Jun Gong et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)

Add to Collection

Article Oncology

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Biotechnology & Applied Microbiology

Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers

Chengcheng Zhang et al.

MOLECULAR THERAPY (2017)

Add to Collection

Article Multidisciplinary Sciences

A molecular portrait of microsatellite instability across multiple cancers

Isidro Cortes-Ciriano et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Genetics & Heredity

Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1

Anita Sveen et al.

GENOME MEDICINE (2017)

Add to Collection

Article Oncology

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

Paul C. Tumeh et al.

CANCER IMMUNOLOGY RESEARCH (2017)

Add to Collection

Article Multidisciplinary Sciences

Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion

Lee A. Albacker et al.

PLOS ONE (2017)

Add to Collection

Article Medicine, General & Internal

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Eric Tran et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Cell Biology

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Jeanne Tie et al.

SCIENCE TRANSLATIONAL MEDICINE (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

Santiago Zelenay et al.

CELL (2015)

Add to Collection

Article Oncology

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

Steven C. Katz et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Article Medicine, General & Internal

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D. T. Le et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Biotechnology & Applied Microbiology

Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy

Mihaela Angelova et al.

GENOME BIOLOGY (2015)

Add to Collection

Article Oncology

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

Nicolas J. Llosa et al.

CANCER DISCOVERY (2015)

Add to Collection

Article Oncology

Colorectal cancer statistics, 2014

Rebecca Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2014)

Add to Collection

Article Multidisciplinary Sciences

Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer

Eric Tran et al.

SCIENCE (2014)

Add to Collection

Article Surgery

A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer

Michael A. Morse et al.

ANNALS OF SURGERY (2013)

Add to Collection

Article Oncology

Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy

Frank A. Sinicrope et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Oncology

Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication

Paul Lochhead et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)

Add to Collection

Article Oncology

Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue

Richard D. Kennedy et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Biotechnology & Applied Microbiology

Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver

Sunil K. Geevarghese et al.

HUMAN GENE THERAPY (2010)

Add to Collection

Article Oncology

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock et al.

LANCET ONCOLOGY (2010)

Add to Collection

Article Oncology

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

Mark E. Dudley et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Review Oncology

Systematic review of microsatellite instability and colorectal cancer prognosis

S Popat et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

Article Multidisciplinary Sciences

Mutations of the BRAF gene in human cancer

H Davies et al.

NATURE (2002)

Add to Collection

Article Oncology

Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability

JR Jass et al.

EUROPEAN JOURNAL OF CANCER (2002)

Add to Collection

Article Pathology

Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings - Parallel pathways of tumorigenesis

J Young et al.

AMERICAN JOURNAL OF PATHOLOGY (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.